Type:Capsule
Generic Name:Gemfibrozil
Manufacturer:Eskayef Pharmaceuticals Ltd.
Price:৳7.00
Hypertriglyceridemia, Hyperlipidemia
Should be taken on an empty stomach. Take ½ hr before meals.
Hypertriglyceridemia, Hypercholesterolemia 600 mg PO q12hr Hepatic impairment Contraindicated
Safety and efficacy not established
Renal impairment Mild to moderate: Use caution, if baseline serum creatine in patient is >2mg/dL; deterioration of renal function reported in such patients Severe: Contraindicated
Hypersensitivity. Severe hepatic or renal dysfunction; gall stones; neonates, children, pregnancy, lactation.
Gemfibrozil exhibits its action by inhibition of lipolysis and reduction of hepatic fatty acid uptake. It also inhibits secretion of VLDL from the liver.
Causes of secondary hyperlipidaemia such as hypothyroidism and diabetes must be treated before initiating therapy. Renal impairment; blood disorders. Periodic monitoring of the serum lipids should be done; if no adequate response after 3 mth, treatment should be withdrawn. May increase risk of cholelithiasis. Lactation: Not recommended
>10% Dyspepsia (20%) 1-10% Abdominal pain (10%),Atrial fibrillation (1%),Diarrhea (7%),Fatigue (4%),N/V (3%),Eczema (2%),Rash (2%),Vertigo (2%),Constipation (1%),Headache (1%) <1% Myalgia,Rhabdomyolysis (especially with admin with statin),Acute appendicitis,Cholelithiasis,Angioedema,Hypokalemia,Eosinophilia,Myopathy,Synovitis,Taste disturbance,Xerostomia,Flatulence,Rash Potentially Fatal: Bone marrow hypoplasia; intracranial haemorrhage; nephrotoxicity; peripheral neuritis.
Co-admin with repaglinide may increase serum levels of repaglinide. May enhance effects of oral anticoagulants. May also increase the plasma concentrations of ciclosporin and associated nephrotoxicity when used concurrently. Potentially Fatal: Increased risk of myopathy and rhabdomyolysis when used with HMG-CoA reductase inhibitors.
